Apart from its antiviral properties, recent studies have indicated that SLFN11 could enhance the sensitivity of cancer cells to DNA-damaging agents (DDAs) and may be a potential robust biomarker to predict response to DDAs in ovarian, lung, and colorectal cancers 11-13. This evidence concerns the gene SLFN11 and cancer.